[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Some permanent long covid", "description": "Link to free download of John\u2019s 2 textbooks.\nhttp://159.69.48.3/       (you may need to cut and paste this link into a brouser)\n\n\nProfiling post-COVID syndrome across different variants of SARS-CoV-2\n\nhttps://www.medrxiv.org/content/10.1101/2022.07.28.22278159v1\n\nAcross all variants\n\nCentral neurological cluster of symptoms\n\nCardiorespiratory cluster of symptoms\n\nDebilitating multi-organ systemic inflammatory symptoms\n\nCentral neurological cluster of symptoms\n\nAnosmia / dysosmia\n\nFatigue\n\nBrain-fog\n\nDepression\n\nDelirium\n\nHeadache\n\n(Largest cluster in both alpha and delta variants, and the second largest for the wild-type variant)\n\nConsistent UK Biobank study\n\nSARS-CoV-2 is associated with changes in brain structure in UK Biobank\n\nhttps://www.nature.com/articles/s41586-022-04569-5?feature%5Bconsent-app%5D=1&optanonConsent=15\n\nReduction in grey matter thickness\n\nTissue damage in primary olfactory cortex\n\nReduction in global brain size \n\nCardiorespiratory cluster of symptoms\n\n(Largest cluster in the wild-type period)\n\nSymptoms may reflect lung damage\n\nDyspnoea\n\nChest pain\n\nFatigue\n\nPalpitations\n\nConsistent study from Medicine\n\nClinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis\n\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772621/\n\nPost-COVID-19 pulmonary fibrosis is a severe complication that leads to permanent lung damage or death.\n\nDebilitating multi-organ symptoms\n\n(Present in all variants)\n\nSystemic/inflammatory\n\nAbdominal symptoms\n\nMyalgias (muscle pain)\n\nVaccination and long covid\n\nwe did not observe evidence of qualitatively different symptom clustering in vaccinated vs. unvaccinated individuals, \n\nwith either alpha or delta variants. \n\nBackground\n\nIt is now evident that post-COVID syndrome presents with heterogeneous profiles,\n\nneed characterisation to enable personalised care\n\nMethods\n\nProspective longitudinal cohort study\n\nN = 336,652 subjects\n\n(Covid Symptom Study)\n\nTested positive\n\nLong-COVID = lasting longer than 28 days\n\nN = 1,459 with post-COVID syndrome (more than 12 weeks of symptoms)\n\nOne in 230 symptomatic, test confirmed cases\n\nClustering analysis, to identify distinct symptom profiles\n\nAcross\n\nVariants of SARS-CoV-2\n\nVaccination status at the time of infection\n\nClusters were characterised\n\nSymptom prevalence\n\nDuration\n\nDemography\n\nPrior conditions (comorbidities)\n\nFindings\n\nWe identified distinct profiles of symptoms for post-COVID syndrome\n\nWild-type variant\n\nFour endotypes identified\n\nAlpha variant\n\nSeven endotypes\n\nDelta variant\n\nFive endotypes in vaccinated subjects\n\nEndotype\n\na subtype of a disease condition, \n\ndefined by a distinct pathophysiological mechanism\n\nInterpretation \n\nOur classification may be useful to understand distinct mechanisms of the post-COVID syndrome, as well as subgroups of individuals at risk of prolonged debilitation.\n\nDr Claire Steves, clinical lead author, King's College London\n\nhttps://news.sky.com/story/three-types-of-long-covid-each-with-different-symptoms-researchers-say-12663531\n\nThese data show clearly that post-COVID syndrome is not just one condition, but appears to have at several subtypes.\n\nUnderstanding the root causes of these subtypes may help in finding treatment strategies.\n\nMoreover, these data emphasise the need for long COVID services to incorporate a personalised approach sensitive to the issues of each individual.\n\nDr Liane Canas, author\n\nThese insights could aid in the development of personalised diagnosis and treatment for these individuals", "link": "https://www.youtube.com/watch?v=F7x5LcUaUVQ", "date_published": "2022-08-04 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Vaccine adverse events, German data", "description": "Safety of COVID-19 Vaccines, German transparent report\n\nhttps://www.pei.de/EN/newsroom/dossier/coronavirus/medicine-safety.html\n\nReports received between 27 December 2020 (start of the vaccination campaign in Germany) and 31 March 2022.\n\nA total of 172,062,925 COVID-19 vaccinations in Germany\n\n296,233 reports of suspected adverse events\n\nOverall reporting rate for all vaccines\n\n1.7 reports per 1,000 doses of vaccine\n\n(0.17%)\n\nReporting rate for serious adverse events\n\n0.2 reports per 1,000 doses of vaccine\n\n(0.02%)\n\n(one per 5,000 doses of vaccine)\n\n\n\n\n6.4. Definitions \n\nAdverse events are noxious and unintended reactions to the medicinal product. \n\n73.3% of vaccine doses Pfizer, (Comirnaty)\n\n17.1% were Moderna (Spikevax)\n\n7.4% were  AstraZeneca AB  (Vaxzevria)\n\n2.1% were COVID-19 Janssen (now called Jcovden)\n\n0.1% were Novavax (Nuvaxovid)\n\nReporting rate after booster vaccinations Pfizer (Comirnaty) or Moderna (Spikevax) was lower than after primary immunisation.\n\nThe Paul-Ehrlich-Institut will closely monitor and continue to investigate cases of,\n\nmyocarditis/pericarditis\n\nthrombosis\n\nimmunologically mediated adverse events such as immune thrombocytopenia,\n\noccurring after administration of the approved vaccines.\n\nFull detailed report\n\nhttps://www.pei.de/SharedDocs/Downloads/EN/newsroom-en/dossiers/safety-reports/safety-report-27-december-2020-31-march-2022.pdf?__blob=publicationFile&v=8\n\n\nGermany, Paul-Ehrlich-Institut, authority responsible for monitoring the safety of vaccines and biomedicines. \n\nInstitute\u2019s Division Pharmacovigilance collects and reviews reports on adverse drug effects,\n\ntakes the necessary steps if required.\n\nReporting suspected cases of adverse effects is a central pillar for being able to judge the safety of medicines. \n\nNew signals can be detected in a timely manner, \n\nand the risk/benefit profile of vaccines can be continuously monitored. \n\nEven reactions with a timely relation to a vaccine do not necessarily have a causal relation.\n\nSafety Reports\n\nOpen communication of risks, including potential ones, is a prerequisite for a high acceptance rate for vaccines among the population. \n\nThe benefit of the COVID-19 vaccination for the health of individuals and the population as well as their effect in combating the pandemic essentially depends on, \n\nConfidence in the vaccination is essential to get benefits of the vaccine\n\nPaul-Ehrlich-Institut publishes continuously all suspected cases reported in Germany,\n\non adverse effects or vaccination complications,\n\nin a temporal relationship with the COVID-19 vaccination.\n\nReporting Portal for Suspected Cases of Adverse Effects\n\nHealthcare providers\n\nMarketing authorisation holder\n\nPersons vaccinated or relatives.", "link": "https://www.youtube.com/watch?v=XlGXFRs4ZOA", "date_published": "2022-08-03 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]